News Snapshot:
BEIJING (REUTERS) - Two Covid-19 vaccines from China's Sinopharm showed more than 70 per cent efficacy against symptomatic cases, but it remains unclear how much protection they provide against severe or asymptomatic cases, according to the first detailed result of a large late-stage study published to the public. A vaccine developed by a Wuhan-based subsidiary of Sinopharm was 72.8 per cent effective against symptomatic Covid-19 at least two weeks after second injection, based on interim results, the peer-reviewed study published in the Journal of the American Medical Association showed on Wednesday (May 26). This is slightly better than the 72.5...
